Literature DB >> 26073308

Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers.

Graham Lappin1.   

Abstract

Obtaining pharmacokinetic data from the intravenous route for drugs intended for oral administration has traditionally been expensive and time consuming because of the toxicology requirements and challenges in intravenous formulations. Such studies are necessary, however, particularly when regulator agencies request absolute bioavailability data. A method has emerged whereby the drug administered intravenously is isotopically labeled and dosed at a maximum of 100 µg concomitantly with an oral administration given at a therapeutically relevant level. The intravenous administration has been termed a microtracer and obviates intravenous toxicology requirements as well as simplifying formulations. The study design also essentially removes issues of nonlinear pharmacokinetics that may occur when oral and intravenous doses are administered separately. This review examines the methodology and the literature to date, including those studies intended for regulatory submission. The method has been extended to the study of prodrug-to-active drug kinetics and to obtaining clearance, volume of distribution, and absolute bioavailability at steady-state conditions.
© 2015, The American College of Clinical Pharmacology.

Keywords:  absolute bioavailability; accelerator mass spectrometry; clearance; intravenous administration; isotopic tracer; microtracer; steady state; volume of distribution

Mesh:

Substances:

Year:  2015        PMID: 26073308     DOI: 10.1002/jcph.569

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

Authors:  L van Andel; H Rosing; Z Zhang; L Hughes; V Kansra; M Sanghvi; M M Tibben; A Gebretensae; J H M Schellens; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  2017-10-17       Impact factor: 3.333

Review 2.  Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology.

Authors:  Jeroen Roosendaal; Hilde Rosing; Jos H Beijnen
Journal:  Clin Pharmacol Drug Dev       Date:  2020-06-22

Review 3.  Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology.

Authors:  Jeroen Roosendaal; Hilde Rosing; Jos H Beijnen
Journal:  Drugs R D       Date:  2020-06

4.  Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose.

Authors:  Jeroen Roosendaal; Stefanie L Groenland; Hilde Rosing; Luc Lucas; Nikkie Venekamp; Bastiaan Nuijen; Alwin D R Huitema; Jos H Beijnen; Neeltje Steeghs
Journal:  Eur J Clin Pharmacol       Date:  2020-05-19       Impact factor: 2.953

5.  Pharmacokinetics, Excretion, and Mass Balance of [14 C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men.

Authors:  Claire Ambery; Graeme Young; Teresa Fuller; Aili L Lazaar; Adrian Pereira; Adam Hughes; David Ramsay; Frans van den Berg; Peter Daley-Yates
Journal:  Clin Pharmacol Drug Dev       Date:  2018-09-19

6.  Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination.

Authors:  Kelly M Mahar; Stephen Caltabiano; Susan Andrews; Bandi Ramanjineyulu; Liangfu Chen; Graeme Young; Adrian Pereira; Alistair C Lindsay; Frans van den Berg; Alexander R Cobitz
Journal:  Clin Pharmacol Drug Dev       Date:  2021-10-28

7.  Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.

Authors:  Andreas Johne; Holger Scheible; Andreas Becker; Jan Jaap van Lier; Peter Wolna; Michael Meyring
Journal:  Invest New Drugs       Date:  2020-03-27       Impact factor: 3.850

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.